International Journal of Reproductive Biomedicine最新文献

{"title":"Response to the letter regarding \"Spontaneous pregnancy following intra-ovarian platelet-rich plasma administration in poor ovarian responders according to the POSEIDON criteria: A cross-sectional study\".","authors":"Roghayeh Anvari Aliabad, Marzie Sanuie Farimani, Kimia Amiri","doi":"10.18502/ijrm.v24i7.21588","DOIUrl":"10.18502/ijrm.v24i7.21588","url":null,"abstract":"","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":"24 7","pages":"639-641"},"PeriodicalIF":1.4,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13594362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149024772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stop gonadotropin-releasing hormone-agonist protocol not superior to antagonist protocol on the outcomes of assisted reproductive techniques in poor responders: A randomized clinical trial.","authors":"Saeideh Dashti, Robab Davar, Fatemeh Emami, Farimah Shamsi, Esmat Mangoli","doi":"10.18502/ijrm.v24i7.21586","DOIUrl":"10.18502/ijrm.v24i7.21586","url":null,"abstract":"<p><strong>Background: </strong>Poor ovarian response remains one of the most challenging problems in assisted reproductive technology. Various stimulation protocols have been proposed to improve outcomes, including combined gonadotropin-releasing hormone (GnRH) agonist and antagonist strategies.</p><p><strong>Objective: </strong>To compare the effectiveness of a stop GnRH-agonist protocol combined with a GnRH-antagonist protocol vs. a standard GnRH-antagonist protocol in poor ovarian responder (POR) cases.</p><p><strong>Materials and methods: </strong>This randomized clinical trial was conducted on 100 women aged 18-44 yr diagnosed as POR according to the Bologna criteria. Participants were randomly allocated to either a GnRH-antagonist protocol (control group) or a combined Stop GnRH-agonist/GnRH-antagonist protocol (intervention group). The primary outcome was the clinical pregnancy rate. Secondary outcomes included the number of retrieved oocytes, embryo quality, chemical pregnancy, and live birth rate.</p><p><strong>Results: </strong>No statistically significant differences were observed between the 2 groups regarding chemical pregnancy, clinical pregnancy, or live birth rates. Laboratory outcomes, including the number of retrieved oocytes, metaphase II oocytes, and embryo quality, were also comparable. The intervention group required a significantly higher gonadotropin dose and had a longer stimulation duration (p <math><mo><</mo></math> 0.01).</p><p><strong>Conclusion: </strong>The stop GnRH-agonist protocol did not demonstrate superiority over the GnRH-antagonist protocol in terms of laboratory or clinical outcomes in POR cases.</p>","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":"24 7","pages":"627-636"},"PeriodicalIF":1.4,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13594363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149024775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of gene polymorphisms in infertility, polyendocrine metabolic ovarian syndrome and recurrent miscarriage in the Iranian women population: A review study.","authors":"Vida Hojati","doi":"10.18502/ijrm.v24i7.21579","DOIUrl":"10.18502/ijrm.v24i7.21579","url":null,"abstract":"<p><p>More than 40% of infertility causes are attributed to women. Polyendocrine metabolic ovarian syndrome (PMOS) is one of the important and common causes of infertility in women. Recurrent miscarriage is defined as the occurrence of 2 or 3 consecutive spontaneous miscarriages before the 20 <math><msup><mrow></mrow> <mtext>th</mtext></msup> </math> wk of pregnancy. The origin of recurrent miscarriage is unknown in 50% of cases, which are called idiopathic recurrent miscarriage. The present study aims to investigate the relationship between gene polymorphisms and infertility, PMOS, and recurrent miscarriage in Iranian women. This review study was conducted by examining reliable domestic and foreign sources between 2000 and 2026. For this purpose, 80 articles were selected and reviewed using the Scientific Information Database, Scopus, ScienceDirect, and PubMed databases, with an emphasis on the most relevant and newest sources. The results of the studies indicate the effective association of some of these gene polymorphisms with infertility, PMOS, and recurrent miscarriage in Iranian women. Some gene polymorphisms also showed no association with the aforementioned diseases. To better understand the association of these polymorphisms with infertility and recurrent miscarriage in women, there is a need for larger populations with more numbers and to study all environmental and climatic aspects of the populations. Investigating the role of different genes in the body's response to various drugs is of great importance in determining appropriate treatment methods and can also be important in population screening.</p>","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":"24 7","pages":"585-604"},"PeriodicalIF":1.4,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13594368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149024717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral dydrogesterone versus oral micronized progesterone: Interim analysis of a randomized controlled trial in pregnant women with threatened miscarriage.","authors":"Alka Kriplani, Ashima Taneja, Gouri Shankar Kamilya, Thirunavukkarasu Ramani Devi, Amol Pawar, Tanusree Gupta, Gayathri Karthik Nagesh, Shilpa Choudhary, Tapan Pattanaik, Monjori Mitra","doi":"10.18502/ijrm.v24i7.21584","DOIUrl":"10.18502/ijrm.v24i7.21584","url":null,"abstract":"<p><strong>Background: </strong>Progestogen/progestin supplementation is favorable in threatened miscarriage. However, comparative data on the efficacy, safety, and immunomodulatory functions of types/routes of administration are limited.</p><p><strong>Objective: </strong>This study compares oral dydrogesterone (DYD) vs. oral micronized progesterone (MP) in threatened miscarriage.</p><p><strong>Materials and methods: </strong>This ongoing, investigator-initiated, randomized controlled trial includes eligible, consenting, pregnant women who had vaginal bleeding and/or abdominal pain during first trimester. Participants are treated up to 14 gestational wk with DYD (40 mg stat followed by 10 mg thrice daily) or MP (200 mg twice daily). The following outcomes till 20 gestational wk are presented: miscarriage rate (primary); change in serum cytokines (interferon gamma [IFN- <math><mi>γ</mi></math> ], tumor necrosis factor alpha [TNF-α], interleukin [IL]-4, IL-10), time to symptom resolution (secondary); treatment-emergent adverse events (AEs; safety).</p><p><strong>Results: </strong>Interim analysis includes 116 participants (DYD, 62; MP, 54). Miscarriage rate in DYD (14.52%) was statistically comparable to, but numerically lower than, that in MP (20.37%; p = 0.558). The mean time to symptom resolution in DYD and MP was, respectively, 6.49 and 7.38 days for vaginal bleeding, and 7.15 and 7.67 days for abdominal pain. Numerically, IFN- <math><mi>γ</mi></math> and TNF-α decreased and IL-4 increased with DYD, while IFN- <math><mi>γ</mi></math> decreased and IL-4 and IL-10 increased with MP. Considering Th1:Th2 ratio, numerical decreases in IFN- <math><mi>γ</mi></math> :IL-4, IFN- <math><mi>γ</mi></math> :IL-10, and TNF-α:IL-4 were evident with DYD but not with MP. No AE was related to study medication.</p><p><strong>Conclusion: </strong>Compared to oral MP, oral DYD resulted in a numerically lower miscarriage rate and time to symptom resolution, concomitant to favorable decrease in Th1:Th2 ratio.</p>","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":"24 7","pages":"605-616"},"PeriodicalIF":1.4,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13594364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149024730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The lactate-myeloid-derived suppressor cells axis in endometriosis from molecular reprogramming to translational therapies: A review article.","authors":"Fatemeh Kiaee, Heshmat Shahi","doi":"10.18502/ijrm.v24i7.21578","DOIUrl":"10.18502/ijrm.v24i7.21578","url":null,"abstract":"<p><p>Endometriosis is a complex chronic condition, driven by estrogen, characterized by the growth of endometrial-like tissue outside the uterus. This often-debilitating disease affects millions of women globally, manifesting as severe pelvic pain, significant subfertility, and a profound reduction in the quality of their lives. These clinical problems need advancements in both diagnostic tools and therapeutic strategies. This article delves into the intricate relationship between endometriosis-derived lactic acid and a specific subset of immune cells, known as myeloid-derived suppressor cells (MDSCs). We aim to elucidate the nuanced biological pathways that affect this significant interaction. Lactates subsequently drive the expansion and activation of MDSCs, which then increase immune suppression through key signaling molecules such as hypoxia-inducible factor 1-alpha, signal transducer and activator of transcription 3, and nuclear factor kappa-light-chain-enhancer of activated B cells. Beyond its role in immune modulation, this complex interplay between lactic acid and MDSCs is emerging as a pivotal factor in the multifaceted pathogenesis of endometriosis. It significantly contributes to the disease's bad progression, including its invasive spread, the development of new blood vessels (angiogenesis), and the characteristic formation of fibrotic, scar-like tissue. This review hypothesizes that targeted modulation of lactate metabolism could serve as a promising therapeutic strategy to regulate MDSC activity. The purpose of this study is to clarify these intricate cellular and molecular events.</p>","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":"24 7","pages":"571-584"},"PeriodicalIF":1.4,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13594361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149024736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole-genome sequencing identifies a potentially causative homozygous splicing variant in <i>RAD54</i> like in non-obstructive azoospermia.","authors":"Razieh Ebrahimi Askari, Agnieszka Malcher, Sara Sadeghzadeh, Rim Ibrahim, Krzysztof Pastuszak, Aashish Srivastava, Seyed Mehdi Kalantar, Serajoddin Vahidi, Nasrin Ghasemi, Maciej Kurpisz","doi":"10.18502/ijrm.v24i7.21585","DOIUrl":"10.18502/ijrm.v24i7.21585","url":null,"abstract":"<p><strong>Background: </strong>Non-obstructive azoospermia (NOA) is a severe form of male infertility characterized by impaired spermatogenesis. Although chromosomal abnormalities and Y-chromosome microdeletions are known causes, many cases remain idiopathic, suggesting that other genetic factors may be involved. RAD54 like (<i>RAD54L</i>) is a key component of the homologous recombination pathway required for DNA double-strand break repair and meiotic progression.</p><p><strong>Objective: </strong>To identify the potential genetic cause of NOA using whole-genome sequencing (WGS) in affected individuals from consanguineous families.</p><p><strong>Materials and methods: </strong>For performing this experimental study, 10 NOA men who were referred to Infertility Center of the Yazd Reproductive Sciences Institute, Yazd, Iran underwent clinical, hormonal, and genetic evaluations. Genomic DNA was extracted from peripheral blood and was subjected to WGS. Variants were filtered and prioritized based on allele frequency, predicted pathogenicity, inheritance pattern, and gene expression data. In silico splicing analyses were performed using SpliceAI and Human Splicing Finder.</p><p><strong>Results: </strong>WGS identified an ultrarare homozygous splice-site variant, c.1375+1G <math><mo>></mo></math> T, in the <i>RAD54L</i> gene. The variant affects a canonical donor splice site and is predicted to cause loss of normal splicing, likely resulting in exon 12 skipping, frameshift, and premature termination codon formation. <i>RAD54L</i> shows the highest expression in testicular tissue and plays a critical role in homologous recombination and meiotic DNA repair. The patient exhibited hormonal findings consistent with primary testicular failure.</p><p><strong>Conclusion: </strong>This study proposes <i>RAD54L</i> as a potential novel candidate gene linked to NOA and underscores the efficacy of WGS in identifying rare genetic etiologies of idiopathic male infertility. Further functional and clinical studies are needed to validate this association.</p>","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":"24 7","pages":"617-626"},"PeriodicalIF":1.4,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13594367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149024710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secular trends in menarche age among Iranian girls: Probit analysis on cross-sectional data of Persian (Shahedieh) cohort.","authors":"Sara Jambarsang, Reyhane Sefidkar, Nooshin Yoshany, Mahsa Khodayarian","doi":"10.18502/ijrm.v24i6.21460","DOIUrl":"10.18502/ijrm.v24i6.21460","url":null,"abstract":"<p><strong>Background: </strong>Given concerns regarding changing puberty ages globally, examining current trends in specific societies is essential.</p><p><strong>Objective: </strong>This study aimed to determine secular changes in the age at menarche among Iranian girls in central Iran using the Probit model.</p><p><strong>Materials and methods: </strong>This cross-sectional study utilized data from the entry phase of the Shahedieh cohort study, Yazd, Iran. In total, fertility information and menarche data were extracted from 4,854 women (aged 35-70 yr). Based on the menarche age data of these individuals, the proportion of those who had reached menarche in each of the 3 birth decades (1946-1957, 1958-1969, and 1970-1981) was calculated. To calculate this proportion, a hypothetical time origin was considered for each decade, and the Probit model was employed to calculate the probability of menarche at each age.</p><p><strong>Results: </strong>Findings indicate that approximately 10% of Iranian girls experienced menarche before age 11, while 90% reached menarche by age 14.89, with a median age of 12.89 yr. A significant downward trend in the age at menarche was observed; girls born between 1946-1957 experienced significantly later menarche compared to those born in the 1958-1969 and 1970-1981 cohorts at the 10 <math><msup><mrow></mrow> <mtext>th</mtext></msup> </math> , 25 <math><msup><mrow></mrow> <mtext>th</mtext></msup> </math> , 50 <math><msup><mrow></mrow> <mtext>th</mtext></msup> </math> , and 75 <math><msup><mrow></mrow> <mtext>th</mtext></msup> </math> percentiles.</p><p><strong>Conclusion: </strong>The observed downward trend in menarche age in central Iran aligns with results from similar studies in developing countries. This declining trend has historically been attributed to lifestyle-related variables. Today, this decreasing trend (acceleration of puberty) can be attributed to poor nutritional habits, sedentary lifestyles, or a physiological response to increased physical and mental stress.</p>","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":"24 6","pages":"527-536"},"PeriodicalIF":1.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13530876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148874228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of non-invasive prenatal screening compared with amniocentesis: A retrospective study.","authors":"Elham Ghadirkhomi, Arezu Norouzi","doi":"10.18502/ijrm.v24i6.21461","DOIUrl":"10.18502/ijrm.v24i6.21461","url":null,"abstract":"<p><strong>Background: </strong>One significant concern during pregnancy is the possibility of chromosomal malformations. While prenatal screenings are intended to reassure parents about the health of their unborn child, how reliable are these results when deemed suspicious?</p><p><strong>Objective: </strong>This study aimed to evaluate the predictive accuracy of non-invasive prenatal screening tests in comparison with amniocentesis as the gold standard diagnostic method for chromosomal abnormalities.</p><p><strong>Materials and methods: </strong>This retrospective descriptive-analytical study was performed using medical records of 490 pregnant women who underwent amniocentesis between 2018 and 2023. Data related to first- and second-trimester maternal serum screening results, ultrasound markers, and fetal karyotype findings were extracted and analyzed.</p><p><strong>Results: </strong>Among 490 pregnant women who underwent amniocentesis, 79 cases were suspected of chromosomal abnormalities based on combined first-trimester ultrasound criteria. Cytogenetic analysis confirmed abnormalities in only 20 of these suspected cases (25.3%). After excluding very low-risk results ( <math><mo>≥</mo></math> 1:300), amniocentesis confirmed abnormalities in only 5.1% (12/234) of first-trimester and 4.5% (7/155) of second-trimester screen-positive cases. All comparisons between screening results and amniocentesis showed significant differences (p <math><mo><</mo></math> 0.05).</p><p><strong>Conclusion: </strong>These findings suggest that a more appropriate clinical approach involves the integrated use of multiple screening tools combined with genetic counseling and clear communication for prenatal care, as well as using validated noninvasive methods such as non-invasive prenatal testing before amniocentesis, thus rationally supporting parents when making decisions. Ultimately, although amniocentesis remains the most accurate diagnostic tool, the goal should be to use all available methods judiciously to minimize unnecessary interventions and psychological harm.</p>","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":"24 6","pages":"537-546"},"PeriodicalIF":1.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13530878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148874108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of intralipid effect on pregnancy outcomes in women with recurrent implantation failure: A retrospective cohort study.","authors":"Atoosa Karimi, Aniseh Dadgar, Haniyeh Saffari, Nazanin Vahedi, Sasan Saket, Soheila Arefi","doi":"10.18502/ijrm.v24i6.21459","DOIUrl":"10.18502/ijrm.v24i6.21459","url":null,"abstract":"<p><strong>Background: </strong>Recurrent implantation failure remains a challenge in assisted reproduction. Intralipid has been proposed as an immunomodulatory intervention to improve outcomes, although evidence remains inconsistent.</p><p><strong>Objective: </strong>This study aimed to evaluate the effect of intralipid on pregnancy outcomes in women with a history of at least 2 failed embryo transfer cycles.</p><p><strong>Materials and methods: </strong>In this retrospective cohort study, data of 270 women with <math><mo>≥</mo></math> 2 failed embryo transfer cycles, who underwent a subsequent frozen embryo transfer (FET) at Avicenna Fertility Center, Tehran, Iran, from March 2021-2022 were extracted from medical records. Participants were allocated to the intralipid group (n = 132), receiving 100 mL intravenous intralipid 20% 1 wk before FET, if beta-human chorionic gonadotropin was positive, the same dose was given every 4 wk until the end of the first trimester, or to the control group (n = 138), undergoing routine FET treatments. Outcomes included biochemical, clinical, and ongoing pregnancy, abortion, and live birth.</p><p><strong>Results: </strong>Biochemical pregnancy rate was significantly higher in the intralipid group compared with controls (51.5% vs. 37.7%, p = 0.022). Clinical pregnancy (43.2% vs. 36.2%), ongoing pregnancy (28.8% vs. 18.8%), and live birth (25.8% vs. 17.4%) also favored the intralipid group, although these differences did not reach statistical significance (p <math><mo>></mo></math> 0.05). Abortion rates were comparable between groups (25.8% vs. 21.0%, p = 0.357).</p><p><strong>Conclusion: </strong>Intralipid may improve biochemical pregnancy rates and shows a non-significant positive trend in other pregnancy outcomes in recurrent implantation failure cases, warranting confirmation in larger randomized controlled trials.</p>","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":"24 6","pages":"517-526"},"PeriodicalIF":1.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13530875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148874231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"The effect of intrauterine injection of autologous peripheral blood mononuclear cells on clinical pregnancy in women with recurrent implantation failure\" [Int J Reprod BioMed, Volume 23, Issue 11, pp. 961-963].","authors":"Ezri Chow, Elean To, Tony Kun Fai Chow","doi":"10.18502/ijrm.v24i6.21466","DOIUrl":"https://doi.org/10.18502/ijrm.v24i6.21466","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.18502/ijrm.v23i11.20551.].</p>","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":"24 6","pages":"550"},"PeriodicalIF":1.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13530879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148874177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}